Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | $236.00 → $422.00 | Neutral → Buy | B. Riley Securities |
| 2/27/2025 | $400.00 → $405.00 | Buy | H.C. Wainwright |
| 6/28/2024 | Neutral | Cantor Fitzgerald | |
| 6/11/2024 | $382.00 | Outperform | Wolfe Research |
| 4/22/2024 | $150.00 | Underperform | BofA Securities |
| 3/15/2024 | $155.00 → $270.00 | Sell → Neutral | B. Riley Securities |
| 3/6/2024 | $382.00 | Buy | Citigroup |
| 2/26/2024 | $155.00 | Neutral → Sell | B. Riley Securities |
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity
B. Riley Securities upgraded Madrigal Pharmaceuticals from Neutral to Buy and set a new price target of $422.00 from $236.00 previously
H.C. Wainwright reiterated coverage of Madrigal Pharmaceuticals with a rating of Buy and set a new price target of $405.00 from $400.00 previously
Cantor Fitzgerald initiated coverage of Madrigal Pharmaceuticals with a rating of Neutral
First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marketable securities of $848.1 million at March 31, 2025Company to host conference call today, May 1, 2025, at 8 a.m. EDT CONSHOHOCKEN, Pa., May 01, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc.
Patients achieved a mean 6.7 kPa reduction in liver stiffness as measured by vibration-controlled transient elastography (VCTE); this represents the largest reduction in liver stiffness reported in a compensated MASH cirrhosis patient population 51% of patients achieved a ≥25% reduction in liver stiffness; a reduction of this magnitude has been associated with reduced progression to end-stage liver diseaseCompany to review topline data during its fourth-quarter and full-year 2024 financial results conference call today, February 26, 2025, at 8 a.m. EST CONSHOHOCKEN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused
Third-quarter 2024 net sales of $62.2 million Rezdiffra™ (resmetirom) coverage goal achieved early, with more than 80 percent of commercial lives covered; less than 5 percent of Rezdiffra-covered lives require biopsy Completed enrollment of clinical outcomes study of Rezdiffra in patients with compensated NASH/MASH cirrhosisReports cash, cash equivalents, restricted cash and marketable securities of $1.0 billion at September 30, 2024Company to host conference call today, October 31, 2024, at 8 a.m. EDT CONSHOHOCKEN, Pa., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic stea